

Pioneering innovative treatments for inflammatory-fibrotic diseases

Adi Mor

Company name-Chemomab----

* Website—www.chemomab.com-

* CEO name---Adi Mor-----

CATEGORY: Biotech/Pharma

SESSIONS

- The heart, the liver, the brain in concert: a year of revolutions in the cardiometabolic space You may delete the section instructions, leaving only the bolded bullet title Answers below should not exceed 60 words per question:

- o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibroinflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

- o Core Technology What is the technology, its uniqueness, and its value proposition? CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that drives the inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases. In clinical and preclinical studies, CM-101 appears safe and active, with the potential to treat multiple fibroinflammatory diseases. Topline data from a Phase 2 trial in PSC is expected midyear 2024.
- o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready